PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) was down 2.4% on Tuesday . The stock traded as low as $1.59 and last traded at $1.60. Approximately 13,274 shares changed hands during mid-day trading, an increase of 50% from the average daily volume of 8,831 shares. The stock had previously closed at $1.64.
PharmaCyte Biotech Stock Performance
The business has a 50 day moving average of $1.79 and a 200-day moving average of $1.91.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Read More
- Five stocks we like better than PharmaCyte Biotech
- The Basics of Support and Resistance
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- Transportation Stocks Investing
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
